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Objective. Recently we reported on the efﬁcacy of imiquimod for treating vulvar intraepithelial neoplasia
(VIN) in a placebo-controlled, double-blinded randomized clinical trial (RCT). Four weeks after treatment, a
complete response was observed in 35% of patients and a partial response in 46%. All complete responders
remained disease-free at 12 months follow-up. In the current investigations, we assessed long-term follow-up
at least 5 years after the initial RCT.
Methods. Twenty-four of 26 imiquimod-treated patients who had participated in the initial RCT were seen
for follow-up. Primary endpoint was durability of clinical response to imiquimod assessed by naked eye
vulvar examination and histology. Long-term clinical response was correlated to lesion size before start of the
initial RCT. Secondary endpoints were mental health, global quality of life, body image and sexual function in
relation with long-term clinical response.
Results. Median follow-up period was 7.2 years (range 5.6–8.3 years). VIN recurred in one of nine
complete responders. Of the initial partial responders, two became disease-free after additional imiquimod
treatment. In the other partial responders, VIN recurred at least once after the initial RCT. In long-term
complete responders, lesion size at study entry was smaller and these patients had a signiﬁcantly better global
quality of life at follow-up than patients with residual disease and/or recurrence after imiquimod treatment.
Conclusions. In case of a complete response, imiquimod is effective in the long-term. Furthermore, patients
with a long-term complete response had a signiﬁcantly better global quality of life than patients who recurred
after imiquimod treatment.
© 2010 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Vulvar intraepithelial neoplasia (VIN) is a premalignant skin
condition that often causes severe and long-lasting pruritus, pain
and psychosexual dysfunction [1]. It can be classiﬁed into differentiated
type VIN, which is associated with lichen sclerosus, and usual type VIN
[2], which is caused by a persistent infection of high-risk human
papillomavirus (hrHPV) [3]. Usual type VIN tends to bemultifocal, and
occurs mainly in younger women [2]. Furthermore, it has a certain
invasive potential: 9% of untreated patients will progress to invasive
vulvar cancer within 1–8 years and 3.3% will progress after treatment
[4].nd Gynecology, Erasmus MC
40, 3000 CA Rotterdam, The
vier OA license.For a long time, surgical removal of all visible lesions was the
standard treatment for VIN [5]. However, surgical treatment often
leads to disﬁgurement, postoperative loss of quality of life and
impaired sexual function [6–8]. In addition, recurrences are common
after surgery, since the underlying cause – a persistent hrHPV
infection – is not cleared [4,9].
The immune response modiﬁer imiquimod was recently introduced
as an alternative for surgery. In a placebo-controlled, double-blinded
randomized clinical trial (RCT), a complete response was observed in
35% of patients and a partial response in 46%, and all complete
responders remained disease-free at 12 months follow-up [10]. More-
over, when the histologic diagnoses were deﬁned in accordance with
the latest International Society for the Study of Vulvovaginal Disease
(ISSVD) VIN terminology [2] in which only VIN is used instead of VIN
1–3, histologic regressionwas complete in 58% of patients. Another RCT,
with a follow-up period of 12 months, reported a complete response
after imiquimod treatment in 81% of patients [11]. However, data on
long-term follow-up after imiquimod treatment are still lacking.
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follow-up periods with median follow-up periods ranging from 5.5 to
30.5 months [10,12]. Therefore, in the current study we have evaluated
durability of clinical response to imiquimod at least 5 years after the
initial RCT [10] in which VIN patients were treated with imiquimod.
Patients and methods
Patients and study design
All imiquimod-treated patients who had participated in our initial
placebo-controlled, double-blinded RCT [10] were invited for an
additional follow-up assessment. During this follow-up visit, we used
the same standard questionnaire as used in the initial RCT to review
changes in medication or smoking habits and asked whether any
treatment for VIN or other premalignant and malignant lesions in the
anogenital tract had occurred since the last follow-up visit at
12 months. All these self reported data as well as detailed clinical
and pathological data obtained from the medical ﬁles were evaluated.
To evaluate long-term response, a vulvar naked eye examination
was performed during the follow-up visit. When vulvar lesions
suspicious for VIN ormalignancywere noted, photographs were taken
of the lesions as described earlier [10]. If no lesions were visible,
photographs were taken of the site of the original lesions treated
during the initial RCT. Photographs taken at the current follow-up
visit were compared with those taken during the initial RCT.
If a recurrence was suspected in those patients who had a complete
response in the initial RCT, a 4-mm punch biopsy was obtained. Biopsy
specimens were used for histologic analysis according to the ISSVD VIN
terminology [2] (reviewed by an experienced gynecologic pathologist
(P.C.E)) and for HPV DNA testing. To compare the presence of HPV in
biopsies taken at follow-up with biopsies taken earlier, the SPF10-LiPA
system (SPF10 HPV LiPA version 1, Labo Biomedical Products, Rijswijk,
the Netherlands) was also performed on biopsy samples taken from
these patients during the initial RCT [13]. Furthermore, long-term
clinical responsewas correlatedwith lesion sizebefore start of the initial
RCT, measured as described earlier [10].
Mental health was assessed with the use of the Medical Outcomes
Study 36-Item Short-form General Health Survey and health related
quality of life was assessed with the European Organization for
Research and Treatment of Cancer (EORTC) quality-of-life question-
naire (QLQ-30) [14–16]. Body image and sexuality were assessedwith
the QLQ-BR23 [17]. These questionnaires had also been used during
the initial RCT.
Primary endpoint was durability of clinical response to imiquimod
assessed by naked eye vulvar examination and, in case a recurrence
was suspected in patients with an initial complete response, by
histologic examination. Secondary endpoints were mental health,
global quality of life, body image and sexual function in long-term
complete responders and in patients with residual disease and/or
recurrence after imiquimod treatment.
All women provided written informed consent for this additional
follow-up assessment and the study was conducted in accordance
with the Declaration of Helsinki and Good Clinical Practice guidelines.
Statistical analysis
Data analysis was performed with the use of the SPSS 15.0
software package for Windows.
Patients were divided in two groups for analyses: patients with a
long-term complete response and patients with residual disease and/or
recurrence after the initial RCT. Data distribution of variables (lesion
size, mental health, global quality of life, body image and sexual
function)was assessedwith theKolmogorov–Smirnov test. Distribution
was normal for all of these variables. Since both groups were similar for
baseline characteristics (age, follow-up period, smoking status, andother HPV lesions, tested with the Mann–Whitney test), differences in
mental health, global quality of life, body image and sexuality were
measured with one-way analysis of variance. Differences in lesion size
before study entryweremeasuredwith theWelch's corrected unpaired
t-test. A two-tailed P value of Pb0.05was chosen to represent statistical
signiﬁcance.
Results
Patients
Twenty-four of the original 26 imiquimod-treated patients
responded and came to our outpatient clinic for an additional follow-
up assessment. Two patients were lost to follow-up assessment; for
these patients data were retrieved from medical ﬁles. One of them had
an initial reduction in lesion size of 26–75% and was treated twice with
laser vaporization after the initial RCT. Recurrence of VIN after the
second laser treatment was treated with vaccination by application of
long peptides from the HPV 16 viral oncoproteins E6 and E7 in another
hospital [18]. She had a partial response to vaccination, and therefore
was treatedwith laser vaporization afterwards. The other patient lost to
follow-up had an initial partial response of 76–99% and was treated
elsewhere for basaloid anal carcinoma, stage T2N0.After treatmentwith
radiotherapy, she had two recurrences of VINwithout invasion andwas
treatedwith local excision. Of the 24 patientswhowere seen for follow-
up, nine had a complete response to imiquimod in the initial RCT, four
had a partial response of 76–99%, six had a partial response of 26–75%,
and ﬁve patients had no response (Table 1). Median age of our study
population at time of current follow-up was 48 years (range,
29–64 years). Median time between the current follow-up visit and
start of the initial RCT was 7.2 years (range, 5.6–8.3 years).
Durability of clinical response in patients initially assessed as complete
responders
Median follow-up period for the complete responders was
7.3 years (range, 5.6–8.3 years). Eight of nine complete responders
had not received any treatment for VIN between the initial RCT and
the current follow-up visit and were still disease-free (Table 1; Figs. 1
and 2). In one of the complete responders a recurrence of VIN was
diagnosed 4 years after the initial RCT at the same location as the
original lesion treated during the RCT, and she was treated with laser
vaporization (Table 1, patient 11). At time of follow-up visit, she again
had a lesion suspect for VIN at the same location and a biopsy was
taken. Histologic diagnosis was VIN, and HPV 16 was detected. A
vulvar biopsy was also taken in three other complete responders to
rule out VIN. Histologically, no VIN was diagnosed in these three
biopsies, and in two of three biopsies no HPV was detected (Table 1,
patients 6 and 7). The third patient presented with condylomata
acuminata, which was histologically conﬁrmed, and an infection with
HPV 6 and HPV 16 was detected (Table 1, patient 8).
Follow-up in patients initially assessed as partial or non-responders
Median time to follow-up of the initial partial and non-responders
was 7.2 years (range, 5.7–8.3 years). All but two partial responders
were treated for their residual lesions by local excision or laser
vaporization. One patient with an initial partial response of 76–99%
had two residual lesions which regressed after an additional
imiquimod treatment for 12 weeks. At time of follow-up visit, she
was still free of disease (Table 1, patient 9 and Fig. 1). Another patient
with an initial partial response of 26–75% had a residual lesion on the
clitoris after treatment in the RCT, and imiquimod was applied once a
week for an additional period of 2 months. She became a complete
responder after treatment and is still disease-free (Table 1, patient 10,
and Fig. 1).
Table 1
Long-term follow-up results in imiquimod-treated patients.
Patient Age Clinical
response
HPV
status
Duration
follow-up
Treatments between 20 weeks
and N5 years follow-up visit
VIN HPV status Vulvar cancer
At N5 year follow-up At 20 weeks At 20 weeks In months 20 weeks and N5 years At N5 years At N5 years
1 53 CR no HPV 100 – no no
2 40 CR no HPV 95 – no no
3 44 CR no HPV 87 – no no
4 56 CR no HPV 91 – no no
5 62 CR no HPV 88 – no no
6 53 CR no HPV 67 – no no HPV no
7 51 CR no HPV 73 – no no HPV no
8 39 CR no HPV 81 condylomata no 6 and 16 no
9 41 PR 76–99% no HPV 93 residual lesion treated with imiquimod no no
10 41 PR 26–75% no HPV 68 residual lesion treated with imiquimod no no
11 42 CR no HPV 84 1 laser yes 16 no
12 38 PR 76–99% 16 86 2 LE no no
13 29 PR 76-99% 16 78 1 LE+laser, 1 LE yes no
14 45 PR 76–99% no HPV 73 1 LEa, 3 imiquimod yes SCC at t=24 months
15 64 PR 26–75% 16 96 1 LE with pudendal ﬂap recontruction no no
16 48 PR 26–75% 16 92 4 LE, 1 imiquimod (stopped due to severe
side effects), 2 laser
no microinvasive SCC at
t=7 months
17 47 PR 26–75% 33 95 2 laser, 1 LE, 1 imiquimod (no response) yes no
18 53 PR 26–75% no HPV 92 did not show up for follow-up visits yes no
19 42 PR 26–75% no HPV 87 1 LE+laser yes no
20 45 no response 16 80 1 LE, 1 laser yes no
21 48 no response no HPV 100 4 LE yes no
22 40 no response 33 80 4 laser, 1 imiquimod yes no
23 52 no response 33 95 3 LE, 1 laser+LE yes microinvasive SCC at
t=38 months
24 48 no response 16 85 1 laser, 1 LE, 1 imiquimod on DRY skin
(periurethral lesion -NCR)
no no
25 b 54 PR 26–75% 16 77 3 laser, 1 vaccination with long peptides from
HPV-16 viral oncoproteins
no data no
26 b 60 PR 76–99% no HPV 83 2 LE no data noc
CR, complete response; HPV, human papillomavirus; LE, local excision; PR, partial response; SCC, squamous cell carcinoma; VIN, vulvar intraepithelial neoplasia.
a Patient was treated with wide local vulvar excision and lymphadenectomy for a squamous cell carcinoma of the left labium majus.
b Data retrieved from medical ﬁles.
c Patient was treated for basaloid anal carcinoma, stage T2N0, with radiotherapy three years after the initial RCT.
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n=2b
Response at >5 years 
Total: n=16
Responsea at 20 weeks
No response
n=5
Weak PR
n=7
Strong PR
n=5
CR
n=9
No response
n=5
Weak PR
n=6
Strong PR
n=4
CR
n=9
CR
n=8
CR
n=1
CR
n=1
CR
n=0
Recurrence
n=1
Residual disease/ 
recurrence
n=3c
Residual disease/
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Fig. 1. Clinical response at 20 weeks, 12 months and N5 years after start of imiquimod treatment. aClinical response at 20 weeks and 12 monthswas classiﬁed as no response (reduction in
lesion size of 25% or less),weakpartial response (PR, 26–75% reduction), strong partial response (76–99% reduction), or complete response (CR, 100% reduction). bOne patientwith aweak
partial response was lost to follow-up at 12 months because of unrelated medical problems, but this patient did show up for long-term follow-up. Another patient with a weak partial
response progressed to invasion (b1 mm)at 7 months. She underwent surgery before follow-up at 12 months, so total lesion sizewas notmeasured at 12 months. cOne patient developed
squamous cell carcinoma at 24 months and was treated with local vulvar excision and lymphadenectomy. dOne patient developed microinvasive squamous cell carcinoma at 38 months
and was treated with local vulvar excision.
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Fig. 2. Clinical results before imiquimod treatment, 4 weeks after treatment and at N5 years follow-up. Clinical pictures of three patients with HPV DNA-positive VIN showing results
before treatment (T=0), 4 weeks after treatment (T=20 weeks) and N5 years after treatment. All three patients showed complete regression of the lesion.
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disease and had one to six treatments for recurrence of VIN between
the initial RCT and the current follow-up visit (Table 1 and Fig. 1).
Most patients were treated with local excision or laser vaporization.
Five of them also received one or more imiquimod treatments during
follow-up (Table 1, patients 14, 16, 17, 22 and 24). Of the patientswith
additional imiquimod treatments, one patient had a VIN lesion next to
the urethra which did not respond during the initial RCT. After the
RCT, she was treated with laser vaporization but had a recurrence
after 1 year. Thereafter she was treated with a periurethral skinning
local excision followed by pudendal transposition to restore the
defect. One year later she suffered once more from a recurrence. She
was again treated with imiquimod, but now she was instructed to
apply the cream after thoroughly drying off the lesion. This resulted in
a complete response (Table 1, patient 24). Of the other four patients
who had additional imiquimod treatments, one patient with no
response during the initial RCT showed a complete response after
2 months of imiquimod treatment but had again a recurrence
5 months later (Table 1, patient 22).
The lesion sizes of long-term complete imiquimod-responders
(Table 1, patients 1–10) were signiﬁcantly smaller than those of
patients with residual disease and/or recurrence (Table 1, patients
11–26) (2.6±2.1 cm2 vs. 9.0±6.7 cm2, P=0.002).
Progression to invasion
One patient with a partial response of 26–75% progressed to
invasion at 7 months as described previously [10]. Depth of invasion
was b1 mm, and a radical excision was performed. She had ﬁve
recurrences of VIN afterwards that did not progress to invasion
(Table 1, patient 16).One patient with no response during the initial RCT had a local
excision for the residual lesions after the RCT, and had a recurrence of
VIN 34 months after start of the initial RCT. Four months later
(38 months after start of the initial RCT), she again had perianal
lesions and a biopsywas taken. Shewas diagnosedwith squamous cell
carcinoma (SCC) with an invasion depth of b1 mm. Additional
excision of the lesion was performed and histologic evaluation
showed VIN, without invasion. Afterwards she had a recurrence of
VIN, for which shewas treatedwith local excision. However, at time of
long-term follow-up visit she again presented with a recurrence
(Table 1, patient 23).
Another patient with a partial response of 76–99% was diagnosed
with SCC located on the left labium majus with an invasion depth of
0.5 cm, 2 years after start of the initial RCT. Wide local vulvar excision
of the tumor with lymphadenectomy was performed, one gland was
positive without extracapsular growth. She is now 4 years post-
treatment and has had no recurrence of the tumor, she did however
have a recurrence of VIN, for which she was treated twice with
imiquimod. She did not respond to the ﬁrst treatment and underwent
a second treatment with imiquimod at time of long-term follow-up
visit. However, during this visit perianal and periclitoral VIN was
diagnosed, and conﬁrmed histologically (Table 1, patient 14).Other hrHPV-related lesions of the anogenital tract
None of the complete responders has been diagnosedwith cervical
intraepithelial neoplasia (CIN) or other hrHPV-related lesions after
completing the initial RCT. Six partial responders had abnormal smear
results between the initial RCT and the current follow-up visit. Two of
these had CIN 1, the other 4 patients had no CIN lesion.
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function
Patients with long-term complete response after imiquimod
treatment (Table 1, patients 1–10) reported a signiﬁcantly better
global quality of life than patients with residual disease and/or
recurrence (Table 1, patients 11–24, P=0.025, Fig. 3). No statistically
signiﬁcant differences were observed between groups in scores on
mental health, body image or sexuality.Discussion
To our knowledge, this is the ﬁrst study reporting on long-term
clinical response of VIN after imiquimod treatment [12]. In this study,
eight of nine complete responders (89%) were still disease-free with a
median follow-up of 7.3 years (range, 5.6–8.3 years). In addition, two
patients with a partial response became complete responders during
follow-up after a prolonged treatmentwith imiquimod. In contrast, all
other partial responders had one ormore recurrences after imiquimod
treatment.
Several studies have indicated that imiquimod is an effective
treatment for VIN. However, since these studies had short follow-up
periods, it is unknown if imiquimod is a safe and effective treatment in
the long term. Previous reported recurrence rates range from 0 to 37%,
with median follow-up periods ranging from 5.5 to 30.5 months [12].
The strength of the current study is the long follow-up period, with a
median follow-up time of 7.2 years (range, 5.6–8.3 years). Althoughwe
were able to retrieve long-term follow-up data of all imiquimod-treated
patients in the initial RCT, a limitation of this study is the relatively small
sample size. Data on recurrences after complete response are based on a
small population, since we had only nine initial complete responders
and two complete responders after prolonged imiquimod treatment.
Our long-term follow-up data demonstrate that 9% (1/11) of
complete imiquimod responders developed a recurrence. This
recurrence rate is lower than that observed for other treatments for
VIN. Reported recurrence rates after surgical treatment are: 0–19%
after vulvectomy [4,19], 15–17% after local excision with free surgical
margins, and 46–50% after local excision with involved surgical
margins [4,9,19,20]. After laser vaporization there is a recurrence in
23–40% of patients [4,19], for photodynamic therapy (PDT) this ﬁgure
is 48% [19].
A possible explanation for the low recurrence rate after imiquimod
treatment could be that – in contrast with surgical treatments – there
is clearance of hrHPV in complete responders, as we demonstrated0
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Fig. 3. Mental health, global quality of life, body image and sexual functioning. Scores
(ranging from 0 to 100, mean±SD) on mental health, global quality of life, body image
and sexual functioning in patients with (Table 1, patients 1–10) and without (Table 1,
patients 11–24) long-term complete response after imiquimod treatment. aPatients
with long-term complete response had a higher score on global quality of life (QoL)
than patients with residual disease and/or recurrence (86±14 vs. 70±17, P=0.025,
one-way analysis of variance).previously [10]. Since HPV infection is the underlying cause of the
disease, VIN is less likely to recur in the patients that clear HPV.
Although the GP5+/6+ PCR enzyme immunoassay [21] was used
during the initial RCT to detect HPV DNA in biopsies taken at 0 weeks
and at 20 weeks,wedecided to use the SPF10-LiPA system, because this
is a more sensitive HPV test [13]. We also tested the biopsies taken
before start of the initial RCT and at 20 weeks from patients who were
biopsied at long-term follow-up with the SPF10-LiPA system. One
patient who was tested HPV negative with the GP5+/6+ PCR enzyme
immunoassay before start of the initial RCT,was testedHPV33 positive
with the SPF10-LiPA system, all other results were similar to the GP5+/
6+ PCR enzyme immunoassay. At long-term follow-up, hrHPV was
detected in the complete responderwith a recurrence (patient 11) and
in the complete responder with perianal condylomata acuminata
(patient 8), the same type (HPV 16)was detected as before start of the
initial RCT. Since these patients had cleared HPV from the biopsied
lesions at 20 weeks, it is likely that they were re-infected with hrHPV.
HPV exclusively infects epithelial keratinocytes and the virus does
not elicit cell death, therefore infection is not accompanied by
inﬂammation, which normally can activate the immune system.
Consequently, it is difﬁcult for the host immune system to recognize
the virus during early stages of infection, which increases the risk for a
persistent infection [22,23]. Imiquimod modulates the immune
response by binding on Toll-like receptors 7 and 8 on the cell surface
of dendritic cells, thereby inducing secretion of pro-inﬂammatory
cytokines [24,25]. In this way, imiquimod alters the local immune
response in favor of clearance of a persistent HPV infection. This
therapeutic strategy is also used in vaccination trials [18,26]. Kenter
recently reported on 20 women with HPV-16-positive VIN that were
vaccinated three or four times with a mix of long peptides from the
HPV 16 viral oncoproteins E6 and E7 [18]. Three months after
vaccination, 5 of 20 patients had a complete response, increasing to 9
of 19 at 12 months after last vaccination (47%). Complete response
rate was maintained at 24 months of follow-up. Complete responders
had a signiﬁcantly stronger response of IFN-γ-associated proliferative
CD4+ T-cells and a broad response of CD8+ IFN-γ T-cells than did
non-responders. Therefore, complete response appeared to be
correlated with induction of HPV-16-speciﬁc immunity. Furthermore,
it has been demonstrated that HPV-16-positive VIN patients with a
pre-existing HPV-speciﬁc type 1 T-cell response are more likely to
have a strong response to imiquimod treatment [27]. Consequently, it
has been suggested to combine imiquimod with HPV vaccination. In
19 VIN patients treated with imiquimod for 8 weeks followed by three
doses of therapeutic HPV vaccination, complete histologic regression
was observed in 32% of women at week 10, increasing to 58% at week
20 and 63% at week 52 [26]. These results are promising, but results of
long-term follow-up are still needed.
In summary, our data indicate that treatmentwith imiquimod is an
effective long-term therapy for VIN. Small lesions are more likely to
respond completely to imiquimod treatment; therefore treatment
period in the initial RCT might have been too short to be effective for
larger lesions. Consequently we advise prolonging the treatment
period until regression has stopped. Finally, despite these positive
results, yearly follow-up visits are still recommended until larger
studies have deﬁnitively demonstrated the long-term effects and
recurrence rate after imiquimod treatment of HPV-induced VIN.Conﬂict of interest statement
The authors declare no conﬂicts of interest.Acknowledgments
We thank Dr. M.N. de Koning for performing the SPF10 HPV LiPA
version 1 test.
162 A. Terlou et al. / Gynecologic Oncology 121 (2011) 157–162References
[1] Preti M, Van Seters M, Sideri M, Van Beurden M. Squamous vulvar intraepithelial
neoplasia. Clin Obstet Gynecol 2005;48:845–61.
[2] Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, et al. Squamous
vulvar intraepithelial neoplasia: 2004 modiﬁed terminology, ISSVD Vulvar
Oncology Subcommittee. J Reprod Med 2005;50:807–10.
[3] Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, et al.
Epidemiology of human papillomavirus infection in men, cancers other than
cervical and benign conditions. Vaccine 2008;26(Suppl 10):K17–28.
[4] van Seters M, van Beurden M, de Craen AJ. Is the assumed natural history of vulvar
intraepithelial neoplasia III based on enough evidence? A systematic review of
3322 published patients. Gynecol Oncol 2005;97:645–51.
[5] Kaufman RH. Intraepithelial neoplasia of the vulva. Gynecol Oncol 1995;56:8–21.
[6] Thuesen B, Andreasson B, Bock JE. Sexual function and somatopsychic reactions
after local excision of vulvar intra-epithelial neoplasia. Acta Obstet Gynecol Scand
1992;71:126–8.
[7] Likes WM, Stegbauer C, Tillmanns T, Pruett J. Pilot study of sexual function and
quality of life after excision for vulvar intraepithelial neoplasia. J Reprod Med
2007;52:23–7.
[8] Likes WM, Stegbauer C, Hathaway D, Brown C, Tillmanns T. Use of the female
sexual function index in womenwith vulvar intraepithelial neoplasia. J SexMarital
Ther 2006;32:255–66.
[9] Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the
natural history and outcome in 405 women. Obstet Gynecol 2005;106:1319–26.
[10] van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ,
et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl
J Med 2008;358:1465–73.
[11] Mathiesen O, Buus SK, Cramers M. Topical imiquimod can reverse vulvar
intraepithelial neoplasia: a randomised, double-blinded study. Gynecol Oncol
2007;107:219–22.
[12] Iavazzo C, Pitsouni E, Athanasiou S, Falagas ME. Imiquimod for treatment of vulvar
and vaginal intraepithelial neoplasia. Int J Gynaecol Obstet 2008;101:3–10.
[13] Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, et al.
Development and clinical evaluation of a highly sensitive PCR-reverse hybridization
line probe assay for detection and identiﬁcationof anogenital humanpapillomavirus.
J Clin Microbiol 1999;37:2508–17.
[14] Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The
European Organization for Research and Treatment of Cancer QLQ-C30: a quality-
of-life instrument for use in international clinical trials in oncology. J Natl Cancer
Inst 1993;85:365–76.[15] Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, et al.
Translation, validation, and norming of the Dutch language version of the SF-36
Health Survey in community and chronic disease populations. J Clin Epidemiol
1998;51:1055–68.
[16] Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and
Interpretation Guide. Boston, MA: New England Medical Center, The Health
Institute; 1993.
[17] Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The
European Organization for Research and Treatment of Cancer breast cancer-speciﬁc
quality-of-life questionnaire module: ﬁrst results from a three-country ﬁeld study. J
Clin Oncol 1996;14:2756–68.
[18] Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon
AP, et al. Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial
Neoplasia. N Engl J Med 2009;361:1838–47.
[19] Hillemanns P, Wang X, Staehle S, Michels W, Dannecker C. Evaluation of different
treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser
vaporization, photodynamic therapy, excision and vulvectomy. Gynecol Oncol
2006;100:271–5.
[20] Modesitt SC, Waters AB, Walton L, Fowler Jr WC, Van Le L. Vulvar intraepithelial
neoplasia III: occult cancer and the impact of margin status on recurrence. Obstet
Gynecol 1998;92:962–6.
[21] van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ.
GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-
throughput identiﬁcation of human papillomavirus genotypes. J Clin Microbiol
2002;40:779–87.
[22] Stanley M. Immune responses to human papillomavirus. Vaccine 2006;24(Suppl
1):S16–22.
[23] Stern PL. Immune control of human papillomavirus (HPV) associated anogenital
disease and potential for vaccination. J Clin Virol 2005;32(Suppl 1):S72–81.
[24] Schiller M, Metze D, Luger TA, Grabbe S, Gunzer M. Immune response modiﬁers–
mode of action. Exp Dermatol 2006;15:331–41.
[25] Schon MP, Schon M. Imiquimod: mode of action. Br J Dermatol 2007;157(Suppl
2):8–13.
[26] Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, et al. Phase II trial of
imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial
neoplasia. Br J Cancer 2010;102:1129–36.
[27] van Poelgeest MI, van Seters M, van Beurden M, Kwappenberg KM, Heijmans-
Antonissen C, Drijfhout JW, et al. Detection of human papillomavirus (HPV) 16-
speciﬁc CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar
intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin
Cancer Res 2005;11:5273–80.
